2024-132 - Sulfonamide-Functionalized Heterocycles as CB2 Receptor Modulators for Neurodegenerative and Autoimmune Diseases

Description:

Background

G-protein-coupled receptors (GPCRs) are pivotal in cell signaling and represent a major target class for drug development. Among them, cannabinoid receptors, especially CB2, play a crucial role in regulating neuroinflammation and immune responses. Current therapeutic options inadequately modulate CB2 activity, limiting effective treatment for neurodegenerative, autoimmune, and chronic pain disorders. There is a strong unmet need for selective, potent compounds capable of precisely targeting CB2 receptors to alleviate these conditions while minimizing side effects.

Technology Description

USC researchers have developed novel sulfonamide-functionalized heterocyclic compounds designed to modulate cannabinoid CB2 receptor signaling. Using ultra-large combinatorial libraries and reliable chemical reactions such as Sulfur Fluoride Exchange (SuFEx), they synthesized diverse triazole- and isoxazole-based molecules. These compounds demonstrate high binding affinity and functional antagonism at CB2, achieving a 55% hit rate in screening assays. This innovative approach provides superior access to new chemical space and improved therapeutic potential compared to traditional drug discovery methods.

Key Advantages

  • High Selectivity: Targets CB2 receptors selectively, reducing off-target effects and improving safety profiles.
  • Innovative Chemistry: Employs advanced SuFEx reactions enabling rapid, diverse compound generation with robust synthetic routes.
  • Proven Efficacy: Demonstrates potent receptor antagonism validated by binding affinity and functional assays.
  • Broad Therapeutic Potential: Applicable for treating neurodegenerative diseases, autoimmune disorders, chronic pain, and cancer.

Stage of Development

  • Synthesis and in vitro functional assays completed
  • Lead compounds identified via virtual screening and biochemical validation

Applications

  • Development of novel therapeutics for neurodegenerative diseases such as multiple sclerosis and neuroinflammation
  • Treatment of autoimmune disorders by regulating immune responses through CB2 modulation
  • Management of chronic pain syndromes with reduced side effects compared to existing cannabinoid treatments
  • Potential adjunct therapies for cancers influenced by cannabinoid receptor signaling

Publications

Key Words

  • CB2 receptor modulators
  • Sulfonamide heterocycles
  • GPCR drug discovery
  • SuFEx combinatorial chemistry

Patent Information:

  • Title: Compounds and Methods for Modulating GPCR Signaling
  • App Type: Nationalized PCT
  • Country: United States
  • Serial No.: 19/628,851
  • Patent No.:  
  • File Date: 9/28/2026
  • Issued Date:  
  • Expire Date:  
  • Patent Status: Patent Pending